Evobright receives full SEED funding

After evaluation of Evobrights proof-of-concept data generated in the preSEED phase starting with the foundation of Evobright in January 2021, the board of the Austria Wirtschafts Service (AWS) has granted full financial support for the SEED phase of Evobright. “It was hard work and many hours went into antibody design and coordination and interaction with multiple CROs and our academic partners. But in the end we achieved all our goals on time and are more than happy to present data that convinced a highly experienced board at the AWS of the feasibility and commercial value of our concept. With SEED financing we can now grow together here at the Vienna science and business hub” says COO Dr. Christoph Baumann. “We are extremely thankful to the AWS, not only for the financial grant but also for the excellent advice and support in networking with reliable external partners. This investment will allow us to further develop our lead candidates and to enter Series A financing with a highly attractive investor package. Hence, it will be the basis or building up our own lab capacities, which will allow us to further increase efficiency and stay ahead of competition” adds CEO Dr. Klaus-Peter Künkele.